Login to Your Account

Vivus Soars Over Obesity Finish Line, Jumps into Partner Race

By Trista Morrison

Thursday, September 10, 2009
Vivus Inc. wowed analysts and investors on Wednesday with better-than-expected data from its final two Phase III trials of obesity drug Qnexa (phentermine/topiramate CR). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription